{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:43:17Z","timestamp":1789983797545,"version":"4.0.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/mcg.0b013e318276be13","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T17:56:20Z","timestamp":1357754180000},"page":"188-192","source":"Crossref","is-referenced-by-count":26,"title":["Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy"],"prefix":"10.1097","volume":"47","author":[{"given":"Guy W.","family":"Neff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Ravinuthala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyingi","family":"Kemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1055\/s-2008-1040322","article-title":"Hepatic encephalopathy.","volume":"28","author":"Cordoba","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R2-20-20210305","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gut.2007.122176","article-title":"Pathogenetic mechanisms of hepatic encephalopathy.","volume":"57","author":"Haussinger","year":"2008","journal-title":"Gut"},{"issue":"suppl 1","key":"R3-20-20210305","first-page":"S3","article-title":"Role of antibiotics in the management of hepatic encephalopathy.","volume":"5","author":"Maddrey","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"R4-20-20210305","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy.","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"R5-20-20210305","first-page":"23","article-title":"Review article: the current pharmacological therapies for hepatic encephalopathy.","volume":"25","author":"Bass","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20-20210305","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/archinte.161.4.525","article-title":"Clostridium difficile-associated diarrhea: a review.","volume":"161","author":"Mylonakis","year":"2001","journal-title":"Arch Intern Med"},{"key":"R7-20-20210305","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1345\/aph.1K675","article-title":"Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.","volume":"42","author":"Garey","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R8-20-20210305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajic.2006.06.004","article-title":"Implications of the changing face of Clostridium difficile disease for health care practitioners.","volume":"35","author":"McFarland","year":"2007","journal-title":"Am J Infect Control"},{"issue":"suppl 1","key":"R10-20-20210305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activitya review.","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"R11-20-20210305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14787210.4.3.417","article-title":"Current and future developments in travelers diarrhea therapy.","volume":"4","author":"Koo","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R12-20-20210305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14656566.2011.546347","article-title":"Biologic properties and clinical uses of rifaximin.","volume":"12","author":"DuPont","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R13-20-20210305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","article-title":"A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers diarrhea.","volume":"142","author":"DuPont","year":"2005","journal-title":"Ann Intern Med"},{"key":"R14-20-20210305","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R15-20-20210305","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/01.mcg.0000225685.37465.e7","article-title":"Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea letter.","volume":"41","author":"Berman","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R16-20-20210305","first-page":"74","article-title":"Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs. vancomycin.","volume":"5","author":"Boero","year":"1990","journal-title":"Microbiol Med"},{"key":"R17-20-20210305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCG.0b013e31814a4e97","article-title":"Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study letter.","volume":"43","author":"Garey","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R18-20-20210305","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.22092","article-title":"Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series.","volume":"16","author":"Neff","year":"2010","journal-title":"Liver Transpl"},{"key":"R19-20-20210305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.","volume":"3","author":"Basu","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"R20-20-20210305","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000320685","article-title":"Therapeutic success of rifaximin for Clostridium difficile infection refractory to metronidazole and vancomycin.","volume":"4","author":"Tannous","year":"2010","journal-title":"Case Rep Gastroenterol"},{"key":"R21-20-20210305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anaerobe.2009.08.004","article-title":"Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.","volume":"15","author":"Johnson","year":"2009","journal-title":"Anaerobe"},{"key":"R22-20-20210305","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.","volume":"9","author":"Nelson","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20-20210305","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R24-20-20210305","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(11)60111-6","article-title":"Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy.","volume":"54","author":"Mullen","year":"2011","journal-title":"J Hepatol"},{"key":"R25-20-20210305","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ajg.2009.615","article-title":"Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective.","volume":"105","author":"Bajaj","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R26-20-20210305","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/bmj.2.6203.1479-a","article-title":"Clostridium difficile-associated colitis after neomycin treated with metronidazole.","volume":"2","author":"Bolton","year":"1979","journal-title":"Br Med J"},{"issue":"suppl 1","key":"R27-20-20210305","first-page":"S10","article-title":"Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.","volume":"5","author":"Williams","year":"2005","journal-title":"Rev Gastroenterol Disord"},{"key":"R28-20-20210305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","article-title":"Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis.","volume":"14","author":"Brigidi","year":"2002","journal-title":"J Chemother"},{"key":"R29-20-20210305","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20-20210305","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/AAC.01143-07","article-title":"Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.","volume":"52","author":"Kokkotou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20-20210305","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.","volume":"23","author":"Pedretti","year":"1991","journal-title":"Ital J Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-201302000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:28:44Z","timestamp":1618036124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201302000-00020"}},"subtitle":["A Retrospective Analysis"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318276be13","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}